Emergent BioSolutions Inc. announced the exercise of a contract option and modification valued at approximately $20 million to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, valued at approximately $7 million, began in December 2024.
The remaining deliveries under this option are expected to be completed in 2025. This procurement falls under Emergent’s existing indefinite-delivery, indefinite-quantity (IDIQ) contract with the DoD, led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
BioThrax is used by all branches of the U.S. military as pre-exposure prophylaxis for anthrax disease. This contract ensures a continued supply of this critical medical countermeasure, reinforcing Emergent's commitment to national preparedness.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.